Drug intelligence / Profile preview

nab-paclitaxel + capecitabine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous, Oral

Overview

nab-paclitaxel + capecitabine is a combination chemotherapy regimen used primarily for the treatment of advanced or metastatic solid tumors, including pancreatic cancer and biliary tract cancers. Nab-paclitaxel (albumin-bound paclitaxel) is a microtubule inhibitor that disrupts cell division by stabilizing microtubules and preventing their depolymerization. The albumin-bound formulation enhances drug delivery to tumor tissue via gp60 receptor-mediated transcytosis and SPARC binding. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase, thereby interfering with DNA synthesis in rapidly dividing cells. This combination has demonstrated substantial antitumor activity as first-line or second-line therapy in metastatic pancreatic cancer and advanced biliary tract cancers, with manageable toxicity profiles[1][5][8]. Nab-paclitaxel was developed by Celgene Corporation; capecitabine was developed by Roche.

Brand names: Abraxane + Xeloda
Other names: albumin-bound paclitaxel + capecitabine

Targets

TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on nab-paclitaxel + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + capecitabine.

Explore the full profile